Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

MMP-9 Protein, Human, Recombinant

Catalog No. TMPY-01248

MMP-9 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 76.3 kDa and the accession number is P14780.

MMP-9 Protein, Human, Recombinant

MMP-9 Protein, Human, Recombinant

Catalog No. TMPY-01248
MMP-9 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 76.3 kDa and the accession number is P14780.
Pack SizePriceAvailabilityQuantity
20 μg$255In Stock
100 μg$5837-10 days
200 μg$9527-10 days
500 μg$1,8207-10 days
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity
Measured by its ability to cleave the fluorogenic peptide substrate, Mca-PLGL-Dpa-AR-NH2. The specific activity is >600 pmoles/min/μg. (Activation description: The proenzyme needs to be activated by APMA for an activated form)
Description
MMP-9 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 76.3 kDa and the accession number is P14780.
Species
Human
Expression System
HEK293 Cells
TagTag Free
Accession NumberP14780
Synonyms
MMP-9,matrix metallopeptidase 9,MANDP2,GELB,CLG4B
Construction
A DNA sequence encoding the human MMP9 zymogen (NP_004985.2) (Met 1-Asp 707) was expressed. Predicted N terminal: Ala 20
Protein Purity
≥ 90 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
MMP-9 Protein, Human, RecombinantMMP-9 Protein, Human, Recombinant
Molecular Weight76.3 kDa (predicted); 80-95 kDa (reducing condition, due to glycosylation)
Endotoxin< 1.0 EU/μg of the protein as determined by the LAL method.
FormulationLyophilized from a solution filtered through a 0.22 μm filter, containing 50 mM Tris, 0.15M NaCl, 0.01MCaCl2, 0.05% Brig-35, pH 7.5. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
ShippingIn general, Lyophilized powders are shipping with blue ice.
Research Background
Matrix metalloproteinases (MMPs) are neutral proteinases that are involved in the breakdown and remodeling of the extracellular matrix (ECM) under a variety of physiological and pathological conditions, such as morphogenesis, differentiation, angiogenesis, and tissue remodeling, as well as pathological processes including inflammation, arthritis, cardiovascular diseases, pulmonary diseases, and tumor invasion. MMP9, also known as 92-kDa gelatinase B/type IV collagenase, is secreted from neutrophils, macrophages, and some transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. It plays an important role in tissue remodeling in normal and pathological inflammatory processes. MMP-9 is a major secretion product of macrophages and a component of cytoplasmic granules of neutrophils and is particularly important in the pathogenesis of inflammatory, infectious, and neoplastic diseases in many organs including the lung. This enzyme is also secreted by lymphocytes and stromal cells upon stimulation by inflammatory cytokines, or upon delivery of bi-directional activation signals following integrin-mediated cell-cell or cell-extracellular matrix (ECM) contacts. Since the integrity of the tissue architecture is closely dependent on the delicate balance between MMPs and their inhibitors, excessive production of MMP-9 is linked to tissue damage and degenerative inflammatory disorders. As a consequence, regulation of gene transcription and tissue-specific expression of MMP-9 in normal and diseased states are being actively investigated to pave the way for new therapeutic targets. Besides, the dramatic overexpression of MMP-9 in cancer and various inflammatory conditions points to the molecular mechanisms controlling its expression as a potential target for eventual rational therapeutic intervention.

Dose Conversion

You can also refer to dose conversion for different animals. More

Calculator

  • Reconstitution Calculator
  • Recombinant Protein Dilution Calculator
  • Specific Activity Calculator

Tech Support

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords